Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haemodynamic Effects of Dobutamine in ATTRwt
NCT06318260Phase 2Recruiting
- Start
- Apr 2024
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dobutamine in transthyretin amyloid cardiomyopathy (ATTR-CM). Primary endpoint: Cardiac output. Started Apr 2024; status: recruiting.
02
Drugs
dobutamine
03
Conditions
transthyretin amyloid cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NCT06318260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06318260.